MMP17: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
(One intermediate revision by the same user not shown)
Line 31: Line 31:
[[Category:Proteases]]
[[Category:Proteases]]
[[Category:Oncology]]
[[Category:Oncology]]
{{No image}}
__NOINDEX__

Latest revision as of 18:13, 17 March 2025


MMP16 (Matrix Metallopeptidase 16) is a member of the matrix metalloproteinase (MMP) family, which is involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis.

Structure[edit]

MMP16 is a zinc-dependent endopeptidase. Like other MMPs, it is synthesized as an inactive proenzyme and is activated when cleaved by extracellular proteinases. The structure of MMP16 includes a pro-domain, a catalytic domain, a hinge region, and a hemopexin-like domain. The catalytic domain contains the zinc-binding motif, which is essential for its enzymatic activity.

Function[edit]

MMP16 is involved in the degradation of various components of the extracellular matrix, including collagen, gelatin, and fibronectin. It plays a critical role in tissue remodeling and repair. MMP16 is also implicated in the activation of other MMPs, such as MMP2, by cleaving their pro-domains.

Clinical Significance[edit]

MMP16 has been associated with various pathological conditions. Overexpression of MMP16 has been observed in several types of cancer, including breast cancer, prostate cancer, and glioblastoma. It is thought to contribute to tumor progression and metastasis by degrading the extracellular matrix and facilitating tumor cell invasion.

In addition to cancer, MMP16 is also involved in arthritis, where it contributes to the degradation of cartilage, leading to joint damage.

Regulation[edit]

The activity of MMP16 is tightly regulated at multiple levels, including gene expression, proenzyme activation, and inhibition by tissue inhibitors of metalloproteinases (TIMPs). TIMP-2 is known to specifically inhibit MMP16 activity.

Research[edit]

Ongoing research is focused on understanding the precise role of MMP16 in various diseases and developing specific inhibitors that could serve as therapeutic agents. MMP16 is a potential target for drug development in cancer therapy and other diseases involving excessive extracellular matrix degradation.

Also see[edit]

Template:Matrix Metalloproteinases